Bromodomain and extraterminal inhibitors block the Epstein-Barr virus lytic cycle at two distinct steps.
J Biol Chem
; 292(32): 13284-13295, 2017 08 11.
Article
em En
| MEDLINE
| ID: mdl-28588024
ABSTRACT
Lytic infection by the Epstein-Barr virus (EBV) poses numerous health risks, such as infectious mononucleosis and lymphoproliferative disorder. Proteins in the bromodomain and extraterminal (BET) family regulate multiple stages of viral life cycles and provide promising intervention targets. Synthetic small molecules can bind to the bromodomains and disrupt function by preventing recognition of acetylated lysine substrates. We demonstrate that JQ1 and other BET inhibitors block two different steps in the sequential cascade of the EBV lytic cycle. BET inhibitors prevent expression of the viral immediate-early protein BZLF1. JQ1 alters transcription of genes controlled by the host protein BACH1, and BACH1 knockdown reduces BZLF1 expression. BET proteins also localize to the lytic origin of replication (OriLyt) genetic elements, and BET inhibitors prevent viral late gene expression. There JQ1 reduces BRD4 recruitment during reactivation to preclude replication initiation. This represents a rarely observed dual mode of action for drugs.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Fatores de Transcrição
/
Proteínas Virais
/
Proteínas Nucleares
/
Regulação Viral da Expressão Gênica
/
Transativadores
/
Herpesvirus Humano 4
/
Fatores de Transcrição de Zíper de Leucina Básica
/
Proteínas de Grupos de Complementação da Anemia de Fanconi
Idioma:
En
Revista:
J Biol Chem
Ano de publicação:
2017
Tipo de documento:
Article